Document is current
Any future updates will be listed below
-
Authors
Salz, Lucia https://orcid.org/0000-0002-4910-7840
Seitz, Alexander
Schäfer, Daniel
Franzen, Julia https://orcid.org/0000-0002-2459-5841
Holzer, Tatjana
Garcia-Prieto, Carlos A.
Bürger, Iris
Hardt, Olaf
Esteller, Manel https://orcid.org/0000-0003-4490-6093
Wagner, Wolfgang https://orcid.org/0000-0002-1971-3217
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (363055819/GRK2415; WA1706/11-1; WA 1706/12-2 within CRU344/417911533; WA1706/14-1; and SFB 1506/1)
Else Kröner-Fresenius-Stiftung (ForTra gGmbH)
Generalitat de Catalunya (CERCA Programme)
European Commission (Next GenerationEU”/PRTR (PDC2022-133476-I00))
Consell Català de Recerca i Innovació (2021 PROD 00020)
Fundación Cellex
- License Information
-
More Information
Article History
Received: 20 December 2022
Revised: 15 June 2023
Accepted: 30 June 2023
First Online: 14 July 2023
Competing interests
: The medical faculty of RWTH Aachen and Miltenyi Biotec have submitted a patent application on the epigenetic signatures described in this manuscript. LS is involved in Meneldor B.V. (), an investment fund with focus on biotech and pharma. DS, TH, IB and OH are employees of Miltenyi Biotec B.V. & Co. K.G. JF is involved in Pryzen UG (). ME is a consultant to Ferrer and Quimatryx. WW is involved in Cygenia GmbH () that may provide services for epigenetic analyses. Apart from this, the authors do not have a conflict of interest.
